Damora Therapeutics, Inc. Earnings Per Share Diluted

• Damora Therapeutics, Inc. showed an increase of +121.5% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2021: $0.50 (loss) per share | Q1 2022: $0.67 (loss) per share | Q2 2022: $0.67 (loss) per share | Q3 2022: $0.54 (loss) per share | Q1 2023: $0.51 (loss) per share | Q2 2023: $0.41 (loss) per share | Q3 2023: $7.50 (loss) per share | Q1 2024: $5.05 (loss) per share | Q2 2024: $4.92 (loss) per share | Q3 2024: $3.39 (loss) per share | Q1 2025: $1.92 (loss) per share | Q2 2025: $2.60 (loss) per share | Q3 2025: $2.36 (loss) per share.
• Over the full 5 years of available data (2021 to 2025), Damora Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 294.1%.
• Historical annual values: Fiscal year 2025: $3.98 per share | Fiscal year 2024: $18.53 (loss) per share | Fiscal year 2023: $36.08 (loss) per share | Fiscal year 2022: $2.43 (loss) per share | Fiscal year 2021: $2.05 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026